legumainbas dna vaccine potent protect breast cancer howe lack safe office oral delivery system restrict clinic applied construct align acid chitosan nanoparticles acne carrier legumain vaccine first test characters acid environs vitro awards electrophoresis data show protect better degrade solute ph cup furthermore size distribute analysis show tend agree form microbes scale complex disperse increase mouse intragastr administer carry gf plasmid express detect intestine peer patch fulllength load differ carrier include attend salmonella typhimurium empty serv control vaccine perform marin orthodox model india tumor volume significantly smaller group use splenocyt cocultur cell prestimul col influence translit cytoplasm plasma membrane fold active cytotox lymphocyte dcdcdc treat compare pb studi suggest coat acid may tool more deli oral effect improv autoimmune response 